PHAXIAM Therapeutics (PHXM) 6-K 2019 Q2 Half-year Financial Report

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE13a-16 OR15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of September 2019

Commission File Number:001-38281

ERYTECH Pharma S.A.

(Translation of registrant’s name into English)

60 Avenue Rockefeller

69008 Lyon France

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form20-F or Form40-F:  ☒  Form20-F  ☐  Form40-F

Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(7):  ☐

INCORPORATION BY REFERENCE

This Report on Form6-K and Exhibit 99.1 to this Report on Form6-K shall be deemed to be incorporated by reference into the registration statement on FormF-3 (FileNo. 333-232669) and registration statements on FormS-8 (File Nos.333-222673 and333-232670), of ERYTECH Pharma S.A. (the “Company”) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Half-Year Financial Report

On September 18, 2019, the Company issued a press release announcing its financial results for the first half of 2019. The Company’s half-year financial report, including its condensed consolidated financial statements as of June 30, 2019, is attached to this Report on Form6-K as Exhibit 99.1.

Exhibits

Reference is made to the Exhibit Index included hereto.

EXHIBIT INDEX

Exhibit	Description
99.1	Half-Year Financial Report, including the Company’s condensed consolidated financial statements as of June 30, 2019.
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ERYTECH Pharma SA
Date: September 26, 2019	By:	/s/ Eric Soyer
		Name Eric Soyer
		Title: Chief Financial Officer and Chief Operating Officer